🥇 First rule of investing? Know when to save! Up to 55% off Investing Pro before BLACK FRIDAYCLAIM SALE

MBX Biosciences earns Buy rating at three investment firms

Published 08-10-2024, 08:06 pm
© Reuters
LLY
-
AZN
-
NVO
-
MBX
-

Investing.com -- Three major investment firms started research coverage of MBX Biosciences stock on Tuesday, each assigning a Buy rating to the biotechnology company.

Analysts at Jefferies highlighted the potential of MBX's lead program, MBX-2109, which is currently in Phase II trials for hypoparathyroidism.

They expressed confidence in the company's scientific platform, particularly in the field of endocrine peptides, noting the possibility of significant improvements in treatment duration and the development of better medicines in established commercial areas.

MBX Biosciences's platform is rooted in the extensive peptide and chemistry research of co-founder Dr. Richard DiMarchi, who brings over 20 years of academic experience and a track record of developing approved therapies. The firm underscored the strength of this scientific foundation, which has been augmented by years of R&D at Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO).

“The lead Phase II program in PTH has shown promising Phase I data with favorable pharmacokinetic (PK),” Jefferies analysts said.

“In 4 doses from 200-900ug MBX-2109 showed dose proportional increase in mean concentration and a 7-9-day half-life, supporting weekly dosing vs competitors that are all daily, with < 2-3 days half-life.”

Looking forward, Jefferies anticipates that MBX stock may benefit from upcoming industry catalysts. These include a strong commercial launch expected from competitor ASND in the first quarter of 2025, which could expand the market for hypoparathyroidism treatments.

Moreover, Phase III data from AstraZeneca PLC (LON:AZN) ADR (NASDAQ:AZN) expected in the first half of 2025 could further validate the platform and potentially increase confidence in MBX's improved weekly dosing regimen.

Separately, Stifel and Guggenheim also started coverage on MBX with a Buy rating and optimistic price targets of $40 and $44, respectively.

Stifel's endorsement is based on the strength of MBX's precision endocrin peptides (PEPs) platform, which is engineered to improve pharmaceutical properties, including reducing injection frequency.

The firm anticipates multiple value-driving catalysts within the next 12 months that could demonstrate the platform's capabilities.

Meanwhile, Guggenheim's analysis points to MBX 2109, a once-weekly peptide targeting a market opportunity that the firm estimates to be over $7 billion.

The anticipation of positive Phase 2 results by the third quarter of 2025 is expected to significantly increase the company's share value.

Furthermore, Guggenheim notes MBX 1416, a once-weekly GLP-1 antagonist, as a potential platform-confirming treatment with expected Phase 1 results in the fourth quarter of 2024. The company “is also in the early stages of developing monthly incretin coagonists for obesity,” analysts highlighted.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.